Henry Mandeville - Concepedia

Author

Henry Mandeville

Royal Marsden NHS Foundation Trust ORCID

Also Known As

Elaine Lousley, H Mandeville, H. C. Mandeville, H. Mandeville, H. Mandeville HC, H.C. Mandeville, HC Mandeville, Henry C Mandeville, Henry C. Mandeville, Henry Mandeville

194

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden NHS Foundation Trust Institute of Cancer Research Royal Marsden Hospital Princess Máxima Center University College London

About

Henry Mandeville is an author at Royal Marsden NHS Foundation Trust specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	1K
2	Health Sciences	11	11	655
3	Engineering	1	1	34
4	Cell Biology	1	1	178
5	Head And Neck Surgery	1	1	36

Henry Mandeville

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT Balaji Ganeshan, Vicky Goh, Henry Mandeville, Radiology	2012	447
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial Gianni Bisogno, Meriel Jenney, Christophe Bergeron, The Lancet Oncology OncologyMedicineDose-intensified DoxorubicinPathologyPharmacotherapy	2018	182
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells Maria Vinci, Anna Burford, Valeria Molinari, Nature Medicine Neuro-oncologyPediatric Brain TumorsSubclonal PopulationsGliomaTumor Heterogeneity	2018	178
Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group Geert O. Janssens, Lorenza Gandola, Stéphanie Bolle, European Journal of Cancer Survival BenefitRadiation TherapyFirst ProgressionMedicineSiop-e-hgg/dipg Working Group	2017	151
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations Sally L. George, Elisa Izquierdo, James Campbell, European Journal of Cancer	2019	90
Fusion status in patients with lymph node‐positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) Soledad Gallego, Ilaria Zanetti, Daniel Orbach, Cancer	2018	80
Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck Q.S. Ng, Henry Mandeville, Vicky Goh, Annals of Oncology Radiation TherapySquamous Cell CarcinomaMedicinePhase Ib TrialProstate Adenocarcinoma	2011	76
European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology Roelof van Ewijk, Reineke A. Schoot, Monika Sparber‐Sauer, Pediatric Radiology	2021	61
Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment Reineke A. Schoot, Olga Slater, Cécile M. Ronckers, European Journal of Cancer Adverse EventsRadiation TherapyMedicineNeck Rhabdomyosarcoma SurvivorsHead And Neck Cancer	2015	57
Consensus Report From the Stockholm Pediatric Proton Therapy Conference Daniel J. Indelicato, Thomas E. Merchant, Normand Laperrière, International Journal of Radiation OncologyBiologyPhysics	2016	54

Page 1